| Proposed Ticker: | ABPI | One Kendall Square, Building 200, Suite 2200 | |
| Exchange: | NASDAQ-Small Cap Market | Cambridge, Massachusetts 02139 | |
| Industry: | Manufacturing | (617) 621-7154 |
| All share information is proposed | ||||
| Type of Shares: | Common Shares | Filing Date: | 12/24/96 | |
| U.S. Shares Filed: | 1,200,000 | Filing Range: | $4.75 - $5.75 | |
| Non-U.S. Shares Filed: | 0 | Offering Amount: | $6,300,000 | |
| Primary Shares: | 1,200,000 | Expenses: | $590,000 | |
| Secondary Shares: | 0 | Shs Out After: | 5,105,348 | |
| Manager | Tier | Phone |
| First United Equity | Lead Manager | (516) 739-4500 |
| Auditor: Eisner, Richard A. | |||||
| 9 Month Ending Financials | |||||
| Audited Income | Latest Unaudited Income | Prior Unaudited Income | Balance Sheet | ||
| 12/31/95 | 9/30/96 | 9/30/95 | 9/30/96 | ||
| Revenue: | $0.00 | $0.18 | $0.00 | Assets: | $0.49 |
| Net Income: | -$0.39 | -$0.22 | -$0.31 | Liabilities: | $0.18 |
| EPS: | -$0.10 | -$0.05 | -$0.08 | Equity: | $0.32 |
Note: Dollar amounts are in U.S. millions; Audited figures expressed as full year, unaudited figures are partial year | |||||
| Business Description |
| The company is a development-stage company engaged in the development of proprietary drugs that protect brain cells from damage caused by disease, injury and aging. The company's target applications include the treatment of Alzheimer's disease, Parkinson's disease, brain damage resulting from stroke and other age-related diseases and conditions. The company's lead product candidates are based on naturally-occurring hormones that have been demonstrated by the company-sponsored research to protect brain cells from damage caused by disease, trauma an aging. The company's major product initiatives are based on estrogen compounds, calcitiol or vitamin D-related compounds and other types of neurosteroids. The company's development activities to date have been based, in large part, on intellectual property it has licensed and research it has sponsored at the medical schools of two universities. The company intends to continue to acquire licenses to intellectual property that could advance the company's product development efforts. |
| Use of Proceeds |
| The proceeds from the proposed offering will be used to fund product development activities, hire additional personnel, establish a small laboratory facility and for general corporate purposes and operating expenses. |
©1996 IPO Data Systems, Inc. - All rights reserved.